Northwest Biotherapeutics (NWBO) is a development stage oncology focused immunotherapy company currently in advanced and mid-stage clinical trials to treat several types of prevalent cancers as well as all solid tumor cancers. New news states, DCVax as a potential life-extending treatment for all solid tumor cancers. Dr. Lee Tessler participating in the Phase III trials for brain cancer at Long Island Brain Tumor Cancer described the process of the immune therapy. Further, Dr. Siegel added that some patients under treatment for Glioblastoma Multiforme (GBM) have experienced a double survival rate as compared to standard cancer therapies - removal of tumor, chemotherapy and radiation. Positive news was that the vaccine takes about eight days for producing enough vaccine for three to five years of treatment. The company is developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, Northwest Biotherapeutics's DCVax as a potential life-extending treatment for all solid tumor cancers by using biomarkers from the patient's own tumor cells to activate the patient's immune system to fight the cancer in the patient's body. According to Dr. Siegel, some patients with Glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer, in preliminary trials have seen their survival times more than double from what would be expected under the current standard of care "Each cancer vaccine is personalized, and it takes just eight days to produce enough for three-to-five years' worth of treatment," remarks Dr. Siegel. "It's more cost-effective than older cancer vaccines, and the side effects are minimal versus standard treatments." "The prognosis for patients receiving standard of care treatment has not materially changed in decades. But DCVax now has the potential to significantly improve and extend the lives of cancer patients suffering from all types of solid tumor cancers, both operable and inoperable, without the toxic side effects associated with existing treatments." The first factor is that the company has received clearance from the FDA to initiate clinical trials for not 1, but all solid tumor cancers of any type. This is a significant event considering that the standard for the FDA is to approve clinical trials on a case-by-case basis per specific indication. The FDA has given Northwest Biotherapeutics an open runway to commence several clinical trials, each holding multi-billion dollar market values, all at once, was a major statement of regulatory support in my opinion. In terms of Northwest Biotherapeutics insider trading, its CEO Linda Powers in the past 12 months has purchased 10,809,992 shares of her company's stock, making her the majority stakeholder in the company and bringing her ownership total to roughly 30% of the company's outstanding shares. She was Formally an Exec at Enron. DCVAX- The patient's immune cells are then harvested and exposed in the laboratory to the biomarkers taken from the patient's tumor. These conditioned immune cells are then injected back into the patient through a simple injection under the skin in the upper arm, similar to a flu shot. The conditioned ("educated") immune cells then mobilize the patient's immune system to now fight any tumor cells bearing the same biomarkers wherever such tumor cells are found in the body. DCVAX-L - Interim results by the Data Monitoring Committee and their recommendation.
Likely it will be a "Continue trial" recommendation, which would be a validation point for institutional investors. However there is a possibility for the DMC to terminate the trial and move all patients to DCVAX-L, given the Phase 1/2 trials had a P value of 0.0003, or less than 3/100th of 1% chance the positive results were due to chance. In this latter outcome, I would expect the SP to go up 2X.
DCVax-D Phase 1 results - Giloblastoma(Brain Cancer) trial as well as its DCVAX-Direct data which showed a complete regression of all tumors in 80%-100% of animals treated with the therapy. (( these tumors did not re-grow))
I am cautiously optimistically expecting positive results. However there is a possibility that this third generation dendritic cell immunotherapy drug of NWBO can give outstanding results. From their original press release, "Building upon the pure immature dendritic cells, NW Bio’s patented methods develop mature and
activated dendritic cells that are far more potent than dendritic cells produced in the standard way.
For example, NW Bio’s dendritic cells produce as much as 10X or more the amount of signaling
compounds which are key to mobilizing other active agents of the immune system, such as T cells
(which infiltrate and attack tumors) and B cells (which produce antibodies)." In this latter outcome, I would expect the SP to go up 2X immediately and an additional 2X the months afterwards. OVER _ALLOTMENT was a success as interest is very high and bodes well for NWBOs future. $4.80 per unit, resulting in gross proceeds of $23,500,000. Northwest also announced today that the underwriter has exercised in full its option to purchase an additional 734,374 units to cover over-allotments. Exercise of the over-allotment option increases the gross proceeds to the Company to $27,025,000.
5.23 +0.24 +4.81%
CLSN best upside in the market
3.50 +0.36 +11.46%
CPRX +4.79% these are leader stocks that are running in the BIO field
nervous novice will kick your short butts as it has done all year. This stock is with great company and the stocks that have kicked bUTTTTT all year. GAINS like 60% with the sector will be made by buying companies like this.
NASDAQ Biotechnology (^NBI) stocks have led the markes all year. This is no surprise for those up 60%. THEY WILL BUY THIS!!!!!!!!!!!!!!!!!!!!!! hold on people as stocks like this is nothing new to the running BIOTECH sector. GO big or go home.
We went through the 50 like hot butter with 4 times average volume. Its clear to almost 5 dollars like you said at the twenty day. the 5 day chart looks great